ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials

Increasing visibility of potential study participants to sites and
sponsors

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug and device
development and commercialisation services to the pharmaceutical,
biotechnology and medical device industries, today announced the release
of its web based patient engagement platform, to provide patients with
study specific information and connectivity with the nearest
investigative site. The solution supplements patient recruitment
outreach by sites and increases visibility of potential study
participants for sponsors and sites.

Patient recruitment specialists work with sponsors to develop outreach
programs that incorporate the right mix of digital channels, traditional
methods and patient advocacy partnerships to attract patients to a study
branded website hosted on the platform. An easy to navigate, user
friendly interface guides the patient to new and ongoing studies in
their particular indication and a pre-qualification questionnaire helps
to determine if the study is a right fit for them. If the patient
decides to register interest, they are given the option to select their
nearest investigative site. This establishes connection with the site
and the patient can then choose to contact the site or ask to be
contacted for pre-screening.

By being able to access the mobile optimised website at home, patients
are able to discuss the possibility of trial participation as a clinical
care option with their family and caregivers. Making it easier for the
patient to register interest will increase access to potential patients
for sponsors. The platform will also enable site staff to see the number
of pre-qualification questionnaires completed in near real-time to
monitor and report on progress to sponsors.

“Access to patients continues to be the biggest challenge for sponsors,
impacting speed to market and overall drug development costs,” commented
EB McLindon, Senior VP Site & Patient Solutions, “We have used our
understanding of patients gained through managing thousands of trials to
develop this patient engagement platform and ease the burden on sites
and patients. This will increase the predictability and speed of patient
recruitment”.

About ICON plc

ICON plc is a global provider of outsourced drug and device development
and commercialisation services to pharmaceutical, biotechnology, medical
device and government and public health organisations. The company
specialises in the strategic development, management and analysis of
programs that support clinical development – from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
employed approximately 13,920 employees in 90 locations in 37 countries
as at March 31, 2019. Further information is available at www.iconplc.com/patient-platform

ICON/ICLR-G

This press release contains forward-looking statements. These
statements are based on management’s current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word “expected” and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC’s website at http://www.sec.gov.

Contacts

ICON Media:
Lucinda Sandon-Allum
Weber Shandwick
+44
(0)2070670548
[email protected]